drugset / Trial / NCT00696787

A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia

NCT00696787

Phase 2 Terminated 125 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate if DVS SR is safe and effective in the treatment of pain associated with fibromyalgia syndrome, and if so to identify the efficacious doses.

Timeline

Start
2008-06
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified 200 mg
Comparator Pregabalin Small molecule 450 mg

Indications